1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome

BACKGROUND: Phase III/IIIb studies demonstrated cabotegravir (CAB) + rilpivirine (RPV) long-acting (LA) dosed every 4 weeks (Q4W) was noninferior to current antiviral regimen (CAR) (FLAIR and ATLAS) and CAB + RPV LA dosed every 8 weeks (Q8W) was noninferior to Q4W (ATLAS-2M) through Week 48 (W48). H...

Descripción completa

Detalles Bibliográficos
Autores principales: Talarico, Christine L, Wu, Sterling, Upadhyay, Ojesh R, Clair, Marty St, Van Eygen, Veerle, Hudson, Krischan J, Griffith, Sandy, Harrington, Conn M, van Lunzen, Jan, Margolis, David, Spreen, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777350/
http://dx.doi.org/10.1093/ofid/ofaa439.1207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777350/
http://dx.doi.org/10.1093/ofid/ofaa439.1207

Ejemplares similares